Opthea (ASX:OPT) completed the final week-52 patient visit in Coast, the first of two phase three trials evaluating a combination therapy candidate for wet age-related macular degeneration, an eye disease that can blur vision, according to a Tuesday Australian bourse filing.
The trial is investigating the superiority and safety of its drug candidate, sozinibercept, in combination with aflibercept, compared with the standard of care alone.
The company is also conducting a concurrent phase three trial assessing the combination of sozinibercept with ranibizumab.
Beyond week 52, patients will continue to be treated for an additional year to evaluate extended safety and tolerability up to a two-year period, the filing said.
Top-line results from the Coast trial are anticipated in the second quarter.
The company's shares were up almost 1% in recent Tuesday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。